<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988425</url>
  </required_header>
  <id_info>
    <org_study_id>2021070701</org_study_id>
    <nct_id>NCT04988425</nct_id>
  </id_info>
  <brief_title>TNFα Monoclonal Antibody for Acute Spinal Cord Injury</brief_title>
  <official_title>Subcutaneous Injection of TNFα Monoclonal Antibody for Treating Traumatic Acute Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kunshan First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kunshan TCM Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi 904 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantong Sixth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhenjiang TCM Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of subcutaneous&#xD;
      injection of TNFα monoclonal antibody cells for the treatment of traumatic acute spinal cord&#xD;
      injury. Spinal cord injury can be divided into three phases, which are acute (within 2&#xD;
      weeks), sub-acute (2 weeks to 6 months), and chronic (over 6 months). The pathological&#xD;
      process of spinal cord injury include primary injury (initial traumatic insult) and a&#xD;
      progressive secondary injury cascade characterized by ischemia, proapoptotic signaling,&#xD;
      peripheral inflammatory cell infiltration and the release of proinflammatory cytokines.&#xD;
      Secondary injury plays a key role in the loss of spinal cord function after trauma. So early&#xD;
      treatment to prevent the secondary injury is the key to improve prognosis. TNFα monoclonal&#xD;
      antibody is a TNF-α inhibitor that could control inflammatory response, and now widely used&#xD;
      in the treatment of Ankylosing spondylitis, Rheumatoid arthritis and other autoimmune&#xD;
      diseases. In this study, the investigators will treat patients with acute spinal cord injury&#xD;
      with TNFα monoclonal antibody and compare with the control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Random grouping</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>American Spinal Injury Association Impairment Scale(ASIA)</measure>
    <time_frame>baseline, 1 month, 3 months, 6 months and 12 months post-treatment</time_frame>
    <description>Change in sensory and motor function as measured by the American Spinal Injury Association Impairment Scale (ASIA). The scale ranked from A to E, A indicates the the most severe spinal cord injury and E indicates no neurological deficit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>1 month post-treatment</time_frame>
    <description>Any abnormal signs, symptoms, findings, or diseases that emerge or worsen relative to baseline in 1 month posttreatment will be recorded as adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Evoked Potentials (MEP) and Somatosensory Evoked Potentials (SSEP) test</measure>
    <time_frame>baseline, 3 months, 6 months and 12 months post-treatment</time_frame>
    <description>Change in sensory and motor function will be measured by SSEP and MED test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual urine test</measure>
    <time_frame>baseline, 3 months, 6 months and 12 months post-treatment</time_frame>
    <description>Change in residual urine as measured by ultrasound test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>TNFα monoclonal antibody group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 500mg of methylprednisolone immediately after admission before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of the same volume of saline immediately after admission before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNFα Monoclonal Antibody</intervention_name>
    <description>Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.</description>
    <arm_group_label>TNFα monoclonal antibody group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Injection of 500mg of methylprednisolone immediately after admission before surgery.</description>
    <arm_group_label>Methylprednisolone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Injection of the same volume of saline immediately after admission before surgery</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged between 18 and 60 years&#xD;
&#xD;
          -  Traumatic spinal cord injury&#xD;
&#xD;
          -  ASIA Impairment Scale A-D&#xD;
&#xD;
          -  The injury must be within two weeks&#xD;
&#xD;
          -  Patients submitted written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Traumatic spinal cord injury with brain injury or peripheral nerve injury&#xD;
&#xD;
          -  Patients with severe multiple injuries and unstable vital signs&#xD;
&#xD;
          -  Non-traumatic spinal cord injury caused by spinal tumors, hematoma, myelitis, etc.&#xD;
&#xD;
          -  Patients with central spinal cord injury&#xD;
&#xD;
          -  Patients with a completely transected spinal cord&#xD;
&#xD;
          -  Patients with fever or acute infection&#xD;
&#xD;
          -  Ongoing infectious disease, such as tuberculosis, HIV, hepatitis, syphilis, etc.&#xD;
&#xD;
          -  Patients with malignant tumour&#xD;
&#xD;
          -  Patients with neurodegenerative diseases, or any neuropathies&#xD;
&#xD;
          -  Patients with ankylosing spondylitis&#xD;
&#xD;
          -  Patients with a previous history of spinal surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuhua Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospotal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuhua Lu, M.D.</last_name>
    <phone>+862181885793</phone>
    <email>xuhualu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bangke Zhang, M.D.</last_name>
    <phone>+8618301783716</phone>
    <email>zbk12345@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Xuhua Lu</investigator_full_name>
    <investigator_title>Director of Traumatic Orthopaedic Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD will be available through email when requested</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

